Business Context and Reporting Period
This Form 8-K is a current report filed by Fluidigm Corporation (not Standard BioTools Inc.) on August 16, 2012. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics
The filing details a public offering of 3,660,000 shares of common stock at a price of $14.25 per share. The filing does not provide historical revenue, profit, cash flow, margins, or debt figures.
- Shares Offered: 3,660,000
- Offering Price: $14.25 per share
- Over-Allotment Option: Up to 549,000 additional shares
- Expected Net Proceeds (Base): Approximately $48.7 million
- Expected Net Proceeds (With Full Over-Allotment): Approximately $56.1 million
Material Changes
The primary material change is the execution of an underwriting agreement with Piper Jaffray & Co. and Cowen and Company, LLC, as joint book-running managers. This represents a significant capital raise event rather than an operational change from a prior period.
Guidance, Outlook, and Risks
The offering is expected to close on August 21, 2012, subject to customary closing conditions. The filing notes that the underwriting agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The document explicitly states it is not intended to provide factual information about the Company beyond the terms of the agreement.
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 21, 2012).
- Confirm whether the underwriters exercised the 30-day over-allotment option for an additional 549,000 shares.
- Review the final prospectus supplement for specific use of proceeds and updated risk factors.
- Check subsequent filings for the actual net proceeds received after deducting all offering expenses.